FDA authorizes JUUL2 and lower-nicotine tobacco, menthol pods

The Food and Drug Administration authorized JUUL Labs on August 28, 2026, to market three JUUL2 products in the United States: the JUUL2 device, a tobacco-flavored pod and a menthol-flavored pod.

The authorized pods contain 18 milligrams of nicotine per milliliter, equivalent to approximately 1.5% to 1.6% nicotine. The device may also be configured to require online-app age verification before it unlocks.

What the FDA action covers

The authorization applies only to the specified JUUL2 device and the two pod varieties. It allows the products to be marketed lawfully through the FDA’s premarket tobacco product application process. It does not authorize every JUUL product, flavor or nicotine strength.

Age verification is an optional device feature, not a universal requirement in every configuration. When enabled, it adds an online age check before the device can be unlocked. The feature does not by itself guarantee that young people cannot obtain or use the products.

Why the FDA authorized the products

For tobacco products, the FDA weighs risks and potential benefits to the population as a whole. That review includes possible benefits for adults who smoke cigarettes and might switch completely to a product that exposes them to lower levels of harmful chemicals, along with risks to youth and adults who do not use tobacco.

Data submitted by JUUL Labs and reviewed by the FDA found that some adult smokers in the studies had stopped smoking combustible cigarettes after six weeks. Among tobacco-pod users, complete-switching rates ranged from 19.9% to 34.6%. Among menthol-pod users, the range was 28.4% to 49.3%.

Those figures are study results, not a guarantee for an individual user. The FDA said the potential health benefit depends on adults switching completely. People who continue smoking while also using e-cigarettes may not receive the same degree of benefit as people who stop smoking cigarettes entirely.

Risks and limits remain

The FDA acknowledged youth-appeal risks associated with the menthol product. It nevertheless concluded that the potential benefit for adults who smoke was sufficient to outweigh those risks for the authorized product.

Nicotine remains addictive, and a lower nicotine concentration does not make JUUL2 risk-free. The FDA continues to warn that people who do not use tobacco should not start using e-cigarettes.

What the authorization does not mean

Marketing authorization is not the same as FDA approval of JUUL2 as a medication. The products are not authorized as smoking-cessation treatments, and the agency is not recommending them for people who do not already use tobacco.

Consumers should also distinguish the confirmed August 28 action from JUUL Labs’ stated intention to seek authorization for additional flavors. The current decision covers the JUUL2 device and the specified tobacco- and menthol-flavored pods.

The FDA says it has now authorized 48 e-cigarette products. Its authorized-products list is the agency’s regulatory reference for e-cigarettes that may be lawfully marketed in the United States.

Sources

• FDA authorization announcement
• Associated Press report on JUUL2 age verification

Look for updates to this story

Related News

• Pennsylvania measles deaths put renewed focus on U.S. vaccination gaps
• FDA Jalapeño Recall Network Reaches Restaurants, Prepared Foods
• FDA approves first drug targeting polycythemia vera biology
• CDC Says U.S. Mpox May Be Moving Toward Endemic Circulation